Ann Lee, Ph.D.

Juno Therapeutics, Inc. (NASDAQ: JUNO), a biopharmaceutical company developing innovative cellular immunotherapies for the treatment of cancer, today announced the appointment of Ann L. Lee, Ph.D., as Executive Vice President of Technical Operations. Dr. Patrick Y. Yang will assume the role of Executive Vice President, Senior Advisor to the CEO. Both will report to Hans Bishop, President and CEO, and work to further advance Juno as a global leader in T cell engineering and manufacturing.

In her new role, Dr. Lee will be responsible for process development, manufacturing, supply chain, quality assurance, and end-to-end process and platform optimization for all aspects of Juno’s engineered T cell product candidates.

Prior to joining Juno, Dr. Lee held senior leadership positions at RocheGenentech, where she served as Senior Vice President and Global Head of Pharma Technical Development, and led a team of more than 2,500 professionals responsible for end-to-end chemistry, manufacturing and control (CMC), and technical support for all pipeline and commercial products. She also spent over 16 years at Merck & Co., Inc., where she led many of the company’s vaccine development efforts and served as project leader for several vaccine products, including quadrivalent human papillomavirus vaccine. She also served as Vice President of Chemical Technology and Engineering in Merck’s Manufacturing Division, where she directed the development, design and start-up of chemical manufacturing facilities, and led supply chain optimization and process improvements for new and licensed products… Continue reading.